Inhibrx (NASDAQ:INBX – Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.
Inhibrx Stock Down 1.9 %
NASDAQ INBX opened at $12.56 on Friday. Inhibrx has a 1-year low of $10.80 and a 1-year high of $18.95. The business’s 50-day simple moving average is $13.86 and its 200-day simple moving average is $14.54.
Wall Street Analyst Weigh In
Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
- Five stocks we like better than Inhibrx
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Using the MarketBeat Dividend Tax Calculator
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
